1. HOME
  2. English TOP
  3. About Us
  4. Message from CEO

Message from CEO

Message from CEO

CEO_Photo

President and CEO :
Koji Tamada, M.D., Ph.D.

Noile-Immune Biotech, Inc. was established as an academia-originated biotechnology company in April 2015 by founders who believe in the great potential of cancer immunotherapy. Based on the results of cancer immunotherapy research that our team has been working on for years, we aim to realize the next generation in cancer immunotherapy with efficacy superior to that of currently available immunotherapy.

The history of cancer immunotherapy research is long; a number of therapies have been proposed and trials to evaluate efficacy of numerous drugs have been performed. The majority of these therapies and drugs were unfortunately not successful in demonstrating efficacy that surpasses that of the conventional standard therapies in large-scale clinical trials. Hence immunotherapy has long been considered not to become a standard therapy for cancer.

Under such situations, groundbreaking progress in tumor immunology since the 1990s has led to successful development of immune checkpoint inhibitors in the early 2010s and regulatory approval of CAR-T cell therapy, which is based on gene-modification technology, in the late 2010s. These immunotherapies exert excellent efficacy in patients who have not responded well to the conventional standard therapies, thereby establishing truly effective cancer immunotherapy. However, further improvement and development of next generation technology are strongly desired as some patients do not demonstrate clinical responses to these cancer immunotherapies and some patients who once responded well experience tumor recurrence.

Capitalizing on our outstanding research and development capabilities, we leverage the latest knowledge and technology irrespective of the existing disciplines in order to pursue our business mainly in CAR-T cell therapy, that is considered as so-called “living drug”. We focus not only on our own in-house development pipelines, but also on co-development pipelines with biotechnology and pharmaceutical companies around the world through partnership based on our platform technology. We carry out our business activities with a view to the coming of the era when we can overcome cancer. “Treating cancer by using the power of the immune system,” and “bringing hope to patients around the world who suffer from cancer” are the founding principles of our company. With these principles in mind, we strive to constantly create novel cancer immunotherapies.